Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics.
Bicycle Therapeutics stock last closed at $6.60, up 0.61% from the previous day, and has decreased 71.58% in one year. It has underperformed other stocks in the Biotechnology industry by 0.21 percentage points. Bicycle Therapeutics stock is currently +8.2% from its 52-week low of $6.10, and -70.94% from its 52-week high of $22.71.
At the moment, there are 69.37M BCYC shares outstanding. The market cap of BCYC is $457.83M. In the last 24 hours, 357,000 BCYC shares were traded.
How to Buy Bicycle Therapeutics Stock
Not sure how to invest in Bicycle Therapeutics stock? Here's how.
Decide where to buy Bicycle Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you figure out where to buy Bicycle Therapeutics stock.
Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
Deposit money your brokerage account: Select your method of payment and add your info.
Analyze Bicycle Therapeutics stock: The Bicycle Therapeutics ticker symbol is BCYC. Is Bicycle Therapeutics stock a good investment? Should you buy shares of BCYC? How do BCYC's underlying business fundamentals look? Do top analysts think Bicycle Therapeutics is a good buy? Why has BCYC's stock price moved recently? (Hint: Our stock analysis website can help you figure out if BCYC is a good stock to buy).
Place your BCYC trade: Decide if you will purchase BCYC shares at the current market price or use a limit order to purchase BCYC shares at a specific price.
Watch your BCYC investment: Create a watchlist to important updates regarding your new investment in Bicycle Therapeutics shares.
Step 1: Decide where to buy Bicycle Therapeutics stock
You need a brokerage account in order to access the NASDAQ market and buy BCYC stock.
A brokerage account allows you to buy and sell a variety of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. Here's why:
Invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
Access to world financial markets: From Tech to Utilities, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open a brokerage account
Now that you've picked the best brokerage, you need to fill out some personal details so you can buy BCYC today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Bicycle Therapeutics stock
Once you have chosen the best place to buy Bicycle Therapeutics stock, it's critical to analyze their stock before you invest, so you truly wrap your head around the risk and opportunity.
Bicycle Therapeutics quick stats
BCYC Price
$6.60
1w %
1.38%
1y %
-71.58%
5y %
-67.52%
P/E
-1.82x
P/B
0.74x
P/S
16.14x
PEG
N/A
Revenue
$28.34M
Earnings
-$250.66M
Fore. Rev. Growth
18.94%
Fore. Earn. Growth
N/A
Market Cap
$457.83M
Next Earnings
N/A
Next Dividend
N/A
Bicycle Therapeutics Due Diligence Checks
WallStreetZen was designed to help everyday investors do more in-depth fundamental analysis in minutes instead of hours.
Last year, BCYC revenue was $28.34M. In the last 5 year, BCYC's revenue has grown by 19.11% per year. This was slower than the Biotechnology industry average of 41.82%.
In the last year, insiders at BCYC have bought more shares than they have sold.
Michael Charles Ferguson Hannay, CHIEF PROD SUPPLY CHAIN OFF of BCYC, was the latest BCYC insider to sell. They sold $2,102.50 worth of BCYC stock on Oct 3, 2025.
No, Bicycle Therapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about BCYC?
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your BCYC trade
There are two main options:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are generally fine for most investors.
Limit order: A limit order lets you buy or sell a stock at a specific price (or better). If you want to ensure you're buying or selling at a specific dollar amount, use a limit order.
Hit the Open button and eToro will execute your order.
If you need additional help with buying stocks on eToro, click the how to video below:
How much does it cost to buy one Bicycle Therapeutics share?
As of Nov 13, 2025, it costs $6.60 to buy one share of Bicycle Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $3, you can buy 0.455 shares of BCYC.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.